Efficacy evaluation of novel oral anticoagulants in patients with cirrhosis accompanied with portal vein thrombosis: a meta-analysis.
10.3760/cma.j.cn501113-20230310-00103
- VernacularTitle:肝硬化伴门静脉血栓患者中使用新型口服抗凝药效果评价的荟萃分析
- Author:
Xiao Tong XU
1
;
Yu Wei LIU
1
;
Jing Lan JIN
1
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
New oral anticoagulants;
Portal vein thrombosis
- MeSH:
Humans;
Portal Vein/pathology*;
Treatment Outcome;
Venous Thrombosis/complications*;
Liver Cirrhosis/pathology*;
Anticoagulants/therapeutic use*;
Hemorrhage
- From:
Chinese Journal of Hepatology
2023;31(6):614-620
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the safety and efficacy of using novel oral anticoagulants (rivaroxaban and others) in patients with cirrhosis accompanied with portal vein thrombosis (PVT). Methods: Clinical research literature published from the establishment of the database to June 20, 2021, was retrieved from PubMed, Web of Science, CNKI, Wanfang, and Weipu databases by combining subject terms and free words. RevMan software was used for the random group meta-analysis model. Results: In terms of PVT recanalization, the novel oral anticoagulants (such as low molecular weight heparin and others) had a higher recanalization rate than traditional anticoagulants (OR = 13.75, 95%CI 3.58-52.9, P = 0.000 1). In terms of bleeding, the novel oral anticoagulants did not increase the risk of bleeding compared with traditional anticoagulants (OR = 2.42, 95%CI 0.62-9.41, P = 0.20). Conclusion: The novel oral anticoagulant drugs are superior to traditional anticoagulants in terms of the occurrence of PVT recanalization; however, there is no statistically significant difference in terms of the occurrence of bleeding between the two groups.
